Rational treatment of cancers Flashcards

1
Q

What are the 4 rational cancer strategies:

A
  1. Induce differentiation
  2. Discourage proliferative signalling
  3. Promote apoptosis
  4. Exploit checkpoint vulnerability
  5. Identify the relevant population for specific strategy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why is cancer incidence falling in large?

A
  1. Storing food better

2. Increased screening of cervical and colorectal cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why has detection improved since the 70s?

A

Encouraging people to look for breast cancer

MRIs increasingly detect smaller growths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the types of tumours and which one do we want to target?

A

Indolent tumours
Aggressive tumours
Intermediate tumours - (potential to disseminate- but can be treated before dissemination and metastases form)
-we want to target aggressive and intermediate tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do we establish if a tumour is aggressive or indolent?

A
Age
size of tumour 
number of lymph nodes in the vicinity that have been affected 
histology
pathological grade
receptor status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What % of people with breast and prostate cancer shouldn’t be treated?

A

80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What test helps identify who really needs treatment?

A

EXPRESSION ARRAY- analysis of gene expression in cancer patients
By using bioinformatics- distinguished 70 distinct ‘prognosis’
prognosis gene expression could then be used to stratify the breast cancer patients
see if these prognosis genes are upregulated or downregulated
by collating this data- it is clear that patients have different profiles
some have a ‘good signature’- low level of metastases - high chance of survival
use this data to make a spectrum- people with a good signature don’t need treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can differentiation stop (one form of) acute promyelocytic leukaemia?

A

Switch off the transcriptional repressor with retinoic acid
proliferation pathway undertaken by the promyelocytes is switched off
blast cells can be induced to differentiate into neutrophils by treatment with all-trans retinoic acid
treatment with ATRA and concomitant chemotherapy often results in complete remissions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does the pathway do awry in promyelocytic leukaemia?

A

Predictable chromosomal rearrangement- translocation involving chromosomes 15 and 17
RA receptor gene breaks off- translocates- fusion with PML gene
RA no longer recognised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What organelle is coded for by PML and how does it change in cancer?

A

PML bodies= nuclear organelle, usually sits in the nucleus

in leukaemia- RA is fused to the PML bodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which 2 compounds can treat acute promyelocytic leukaemia?

A

All-trans retinoic acid (RA derivative)

Arsenic trioxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does arsenic trioxide work?

A

ARO3 promotes ubiquitin ligase to specifically target the PML fusion protein- drives it to the proteasome
All-trans retinoic acid mechanism is essentially the same

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How can we exploit checkpoint vulnerability in cancer cells?

A

In hepatoma cells- treat them with doxorubicin- DNA damaging drug that normally induces G2 arrest-
mitotic catastrophe= fragmented nuclei
cancer cells killed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why is it difficult to target tumour suppressor genes in cancer cells?

A

LOH is a traditional phenotype in cancer cells- theyve lost both copies of the TSG- its not there
running out of enzymatic targets in terms of inhibiting things
we want a GOF in tumour suppressor genes, instead of inhibiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why can we exploit checkpoint vulnerability in cancer cells but not WT cells?

A

WT cells- induce DNA damage-checkpoint ensure that there is a cell cycle delay- waiting for repair/stress to be removed- if you block cells in s phase- all replication forks stop-
there is no delay/stop in cancer cells- they will attempt DNA replication, and will complete G2 even if there is no replicated DNA- this leads to mitotic catastrophe= CELL DEATH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What does PRIMA1 do?

A

Small molecule that covalently attaches to mutant p53 and induces a shape change-
has the ability of reintroducing apoptosis

17
Q

How can we see that cells are going through apoptosis?

A

FACS analysis

sub G1 population= apoptotic cells

18
Q

What is Nutlin2?

A

A protein-protein inhibitor

inhibits mdm2 from binding p53- and therefore prevents the destruction of p53 in the proteasome

19
Q

Which CDKIs block the phosphorylation and inactivation of rb?

A

p21 and p27

20
Q

What drug increases P27 levels? And when is it used?

A

In ovarian cancer

vr54 increases the expression of p27 in a concentration-dependent manner

21
Q

What are the features of a druggable target?

A

Cavity vulnerable to low MW compound
inhibit the function of the cavity
disrupt catalytic activity- catalysis ususally amplifies a signal, so inhibiting catalysis can have a large impact on the pathway
Lots of points of contact for drugs

22
Q

Examples of undruggable targets

A

Myc and fos

23
Q

Examples of druggable targets

A

v-EGF-R and Abl

24
Q

What does gleevec do?

A

Sits in the catalytic cleft of the Abl protein kinase

kinase cannot bind ATP

25
Q

Why are kinases good targets?

A

Many protein kinases are oncogenes

they are usually upregulated/ mutated to be permanently switched on

26
Q

Why are kinases bad targets?

A

Protein kinases have evolved from a common ancestor- ATP binding site similar across all PKs
-despite this there is enough variation in the ATP binding site for competitive inhibitors to be produced

27
Q

Whats a molecule that is specific to EGF-R?

A

Tarceva - tyrosine kinase inhibitor

28
Q

What is cetuximab and when is it not effective?

A

Humanised monoclonal antibody against EGF-R
binds to the top part of the receptor
it’s no good when the receptor has mutated and the extracellular domain is lost- ligand independent firing
-used to treat metastatic colorectal cancer and non-small cell lung cancer

29
Q

Why is resistance an issue with clinical trials?

A

To make a clinical trial valid- need people from all the subsets of a cancer- including resistant and sensitive types- becomes more and more complex with fewer people available= statistical power reduces

30
Q

What does BCR-ABL fusion result in?

A

An oncogene
some tumours are resistance to Gleevec- which inhibits Abl
there are some tumours which are less sensitive

31
Q

What’s one way of getting round resistance?

A

Predict when resistance will arise
develop inhibitors that will be first and second generation inhibitors and anticipate mutations
Another way= multi-pronged approach
switch from one rational cancer strategy to another- avoid the selective pressure and approach the cancer is a new way

32
Q

Why do cynics argue that we should not try and ‘treat’ aggressive forms of cancer?

A

They will become lethal no matter what therapy is used (truly effective treatments of most kinds of metastases are not available at present)

33
Q

How has gene expression arrays and bioinformatics helped breast cancer diagnosis?

A

They have increased the accuracy of predicting the course of breast cancer progression to more than 90%

34
Q

What’s the issue with B-cell lymphomas (myelomas)?

A

They have very variable outcomes- can survive 3 weeks or 10 years
tumours have a very similar appearance under the microscope
gene expression analysis has allowed us to distinguish between the types
-B-cell lymphomas (PMBL)
-B-cell like lymphomas (GCB)
-Activated B-cell like lymphomas (ABC)

35
Q

Which B cell lymphomas can be targeted, why can the other type be targeted in this way?

A

ABCs and PMBLs exhibit constitutively high levels of NF-kb activity
this transcription factor drives proliferation and protects them from apoptosis
Can use an IKK inhibitor- acts upstream of the pathway- - kills the tumour cells
GCB show low levels of NF-kb activity and thus remain essentially unaffected by this treatment